LBL-007 Injection

DRUG3 trials

Sponsors

Nanjing Leads Biolabs Co.,Ltd

Conditions

Advanced Malignant TumorsAdvanced MelanomaMalignant Tumors

Phase 1

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

CompletedNCT05102006

Nanjing Leads Biolabs Co.,LtdAdvanced Malignant Tumors

Start: 2021-11-30End: 2024-05-22Updated: 2025-06-03

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

CompletedNCT05516914

Nanjing Leads Biolabs Co.,LtdMalignant Tumors

Start: 2022-09-01End: 2026-01-30Updated: 2026-04-01

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

RecruitingNCT07099430

Nanjing Leads Biolabs Co.,LtdAdvanced Melanoma

Start: 2025-09-05End: 2027-12-30Target: 200Updated: 2025-12-04

Related Papers

Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

Journal of Clinical Oncology2025-05-28

Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

Cancer Research2024-04-051 citations